. 2019 May 29;18:126. doi: 10.1186/s12944-019-1051-2

Table 2.

Effect of Doxorubicin (DOX) and different treatments of AHE on hepatic POD, SOD, CAT and QR status

Treatment (mg/kg)	POD (U/min)	SOD (U/mg protein)	CAT (U/min)	QR (nM/min/mg protein)
Control	13.40 ± 0.225^b	1.547 ± 0.0592^b	24.02 ± 0.077^b	104.8 ± 1.006^b
DOX	6.090 ± 0.589^a	0.3824 ± 0.054^a	12.72 ± 0.044^a	64.79 ± 1.070^a
AHE alone	13.09 ± 0.266^b	1.553 ± 0.0814^b	24.03 ± 0.026^b	104.7 ± 1.065^b
DOX + AHE (200)	9.06 ± 0.271^{a, b, d}	1.063 ± 0.0364^{a**, b}	15.43 ± 0.063^{a, b, d}	76.81 ± 0.476^{a, b, d}
DOX + AHE (400)	12.09 ± 0.179^{b, c}	1.371 ± 0.0794^{b, c*}	20.83 ± 0.058^{a, b, c}	94.87 ± 1.433^{a, b, c}
DOX + Sily	12.20 ± 0.237^b	1.323 ± 0.0566^b	20.90 ± 0.088^{a, b}	93.40 ± 1.440^{a, b}

Values expressed as mean ± SEM. ^a Significance at p < 0.0001 Vs. control group, ^b Significance at p < 0.0001 Vs. Doxorubicin (DOX) group, ^c Significance at p < 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. ^d Significance at p < 0.0001 of AHE co-treatment groups Vs DOX + Sily group. ^{*, **} Significant difference at p < 0.05 and p < 0.001 respectively. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey’s multiple comparison tests). Sily-Silymarin